(0.09%) 5 522.00 points
(0.13%) 39 897 points
(0.20%) 19 790 points
(-0.01%) $81.62
(0.53%) $2.83
(-0.28%) $2 337.90
(0.19%) $29.58
(0.28%) $1 004.60
(0.00%) $0.931
(-0.04%) $10.53
(-0.01%) $0.788
(-0.84%) $87.25
-0.96% $ 3.09
Live Chart Being Loaded With Signals
Tenaya Therapeutics, Inc., a biotechnology company, discovers, develops, and delivers therapies for heart disease in the United States. It develops its products through cellular regeneration, gene therapy, and precision medicine platforms...
Stats | |
---|---|
Dzisiejszy wolumen | 283 875 |
Średni wolumen | 301 690 |
Kapitalizacja rynkowa | 242.62M |
EPS | $-0.400 ( Q1 | 2024-05-14 ) |
Następna data zysków | ( $-0.400 ) 2024-08-14 |
Last Dividend | $0 ( N/A ) |
Next Dividend | $0 ( N/A ) |
P/E |
-1.870 (Sector) 42.63 (Industry) 24.32 |
ATR14 | $0.00500 (0.16%) |
Date | Person | Action | Amount | type |
---|---|---|---|---|
2024-03-05 | Hoey Timothy | Sell | 3 300 | Common Stock |
2024-02-23 | Hoey Timothy | Buy | 12 500 | Common Stock |
2024-02-23 | Hoey Timothy | Buy | 75 000 | Stock Option (Right to buy) |
2024-02-23 | Tingley Whittemore | Buy | 215 000 | Stock Option (Right to buy) |
2024-02-23 | Tingley Whittemore | Buy | 35 000 | Common Stock |
INSIDER POWER |
---|
99.29 |
Last 96 transactions |
Buy: 62 840 535 | Sell: 9 767 330 |
Wolumen Korelacja
Tenaya Therapeutics, Inc. Korelacja
10 Najbardziej pozytywne korelacje | |
---|---|
AVIR | 0.893 |
TATT | 0.869 |
ADP | 0.848 |
IDYA | 0.845 |
FAT | 0.826 |
VSTM | 0.824 |
BASE | 0.819 |
ICHR | 0.805 |
URBN | 0.803 |
Did You Know?
Correlation is a statistical measure that describes the relationship between two variables. It ranges from -1 to 1, where -1 indicates a perfect negative correlation (as one variable increases, the other decreases), 1 indicates a perfect positive correlation (as one variable increases, the other increases), and 0 indicates no correlation (there is no relationship between the variables).
Correlation can be used to analyze the relationship between any two variables, not just stocks. It's commonly used in fields such as finance, economics, psychology, and more.
Tenaya Therapeutics, Inc. Korelacja - Waluta/Towar
Tenaya Therapeutics, Inc. Finanse
Annual | 2023 |
Przychody: | $0 |
Zysk brutto: | $-8.69M (0.00 %) |
EPS: | $-1.680 |
FY | 2023 |
Przychody: | $0 |
Zysk brutto: | $-8.69M (0.00 %) |
EPS: | $-1.680 |
FY | 2022 |
Przychody: | $0 |
Zysk brutto: | $-8.71M (0.00 %) |
EPS: | $-2.76 |
FY | 2021 |
Przychody: | $0.00 |
Zysk brutto: | $0.00 (0.00 %) |
EPS: | $-0.00269 |
Financial Reports:
No articles found.
Contract Name | Last Trade Date (EDT) | Strike | Last Price | Bid | Ask | Change | % Change | Volume | Open Interest | Implied Volatility | Strike Date |
---|---|---|---|---|---|---|---|---|---|---|---|
No data available |
Contract Name | Last Trade Date (EDT) | Strike | Last Price | Bid | Ask | Change | % Change | Volume | Open Interest | Implied Volatility | Strike Date |
---|---|---|---|---|---|---|---|---|---|---|---|
No data available |
Tenaya Therapeutics, Inc.
Tenaya Therapeutics, Inc., a biotechnology company, discovers, develops, and delivers therapies for heart disease in the United States. It develops its products through cellular regeneration, gene therapy, and precision medicine platforms. The company is developing TN-201, an adeno-associated virus (AAV)-based gene therapy to address genetic hypertrophic cardiomyopathy (gHCM) caused by haploinsufficient myosin binding protein C3 (MYBPC3) gene mutations; and TN-301, a small molecule inhibitor of histone deacetylase 6 (HDAC6i) for use in heart failure with preserved ejection fraction (HFpEF) and genetic dilated cardiomyopathy (gDCM). It is also developing TN-401, an AAV-based gene therapy that addresses genetic arrhythmogenic right ventricular cardiomyopathy (gARVC) caused by plakophilin 2 (PKP2) gene mutations; an AAV-based gene therapy designed to deliver the dwarf open reading frame (DWORF) gene in the heart for DCM; and Reprogramming program, an AAV-based approach for cardiac regeneration to replace heart cells lost in patients experiencing heart failure due to prior myocardial infarction. The company was incorporated in 2016 and is headquartered in South San Francisco, California.
O Sygnały na żywo
Prezentowane na tej stronie sygnały na żywo pomagają określić, kiedy KUPIĆ lub SPRZEDAĆ BRAK DANYCH. Sygnały mogą mieć opóźnienie wynoszące nawet 1 minutę; jak wszystkie sygnały rynkowe, istnieje ryzyko błędu lub pomyłki.
Sygnały transakcyjne na żywo nie są ostateczne i getagraph.com nie ponosi odpowiedzialności za żadne działania podjęte na podstawie tych sygnałów, jak opisano w Warunkach Użytkowania. Sygnały opierają się na szerokim zakresie wskaźników analizy technicznej